Complement Factor H (CFH) is the principal soluble regulator of the alternative pathway of the complement system, a critical component of the innate immune system[@ricklin2010]. As a 155 kDa glycoprotein composed of 20 short consensus repeat (SCR) domains, CFH plays an essential role in distinguishing self from non-self tissues by preventing complement-mediated damage to host cells while facilitating the clearance of pathogens and cellular debris. Beyond its well-established role in age-related macular degeneration (AMD)[@klein2005], emerging research demonstrates that CFH and the complement system more broadly participate in neuroinflammation, synaptic pruning, and microglial activation���all processes central to neurodegenerative disease pathogenesis[@veerhuis2011].
| CFH Protein | |
|---|---|
| Protein Name | Complement Factor H |
| Gene | [CFH](/genes/cfh) |
| UniProt ID | [P08603](https://www.uniprot.org/uniprot/P08603) |
| PDB ID | 3rzw, 4b80, 5o39 |
| Molecular Weight | 155 kDa |
| Length | 1,211 amino acids |
| Subcellular Localization | Plasma, Extracellular space |
| Protein Family | Regulators of complement activation |
CFH acts as the primary regulator of the alternative pathway of complement activation, functioning to:
In the central nervous system, complement proteins including CFH are produced by astrocytes, microglia, and neurons. Local complement activation occurs in Alzheimer's disease (AD)[@stancu2014], Parkinson's disease (PD)[@bonotis2016], multiple sclerosis (MS)[@zipp2010], and amyotrophic lateral sclerosis (ALS)[@zhou2020], where CFH dysregulation contributes to neuroinflammatory processes and synaptic loss.
Factor H is a 1,211-amino acid glycoprotein (approximately 155 kDa) composed of 20 short consensus repeats (SCRs, also called complement control protein modules or CCP modules), each approximately 60 amino acids in length, connected by short linker peptides[@morris2013].
| Domain | Amino Acids | Function |
|---|---|---|
| SCR1-4 | 1-240 | Primary C3b binding site; cofactor activity |
| SCR5-8 | 241-480 | Heparin and C3d binding; cell surface recognition |
| SCR9-15 | 481-900 | Additional C3b binding; regulatory activity |
| SCR16-18 | 901-1080 | Dimerization interface; self-protection |
| SCR19-20 | 1081-1211 | Surface recognition; anchor to host cell membranes |
The elongated, flexible structure allows CFH to simultaneously interact with multiple complement components and cell surface glycans. Each SCR domain contains four conserved cysteine residues forming two disulfide bonds that stabilize the fold. The flexibility between SCR domains enables CFH to adopt various conformations for substrate recognition[@yang2013].
The CFH gene contains several polymorphisms associated with increased disease risk:
Factor H is the primary soluble regulator of the alternative pathway of complement activation, functioning through multiple mechanisms[@singhroute2012]:
CFH serves as an essential cofactor for serine protease factor I to cleave and inactivate C3b. This prevents runaway amplification of the alternative pathway, which can deposit hundreds of C3b molecules on a target surface. Without CFH, spontaneous C3 activation in plasma would lead to uncontrolled complement consumption[@ricklin2010].
CFH accelerates the dissociation (decay) of the C3 convertase (C3bBb), the enzymatic complex that cleaves C3 into C3a and C3b. By dissociating the convertase, CFH limits the generation of additional C3b molecules.
CFH binds to host cell surfaces via glycosaminoglycans (heparin, chondroitin sulfate) through its SCR7-15 domains. This localization directs CFH to protect self-tissues while allowing complement activation on foreign surfaces lacking appropriate glycosaminoglycan patterns.
Circulating at high plasma concentrations (0.3-0.5 mg/mL), CFH provides systemic protection against accidental complement activation on host tissues.
In Alzheimer's disease, complement activation and CFH play complex roles in amyloid-β plaque pathology and neuroinflammation[@stancu2014]:
Aβ and Complement Interaction: Amyloid-β (Aβ) peptides can directly activate the alternative pathway of complement, generating C3a and C5a anaphylatoxins that recruit and activate microglia. CFH normally limits this activation, but CFH can be recruited to Aβ plaques via its amyloid-binding properties.
CFH in Plaques: Immunohistochemical studies demonstrate CFH and other complement proteins co-localize with amyloid plaques in AD brain[@veerhuis2011]. CFH may attempt to limit complement-mediated inflammation but becomes overwhelmed or dysfunctional.
Genetic Association: CFH polymorphisms, particularly Y402H, have been investigated in AD risk, with some studies suggesting modest associations with disease onset or severity. The Y402H variant shows altered binding to Aβ and inflammatory mediators[@shi2021].
Microglial Activation: The complement system, including CFH-regulated pathways, influences microglial phenotypic activation. C1q and C3b opsonize synapses for elimination by microglia. CFH regulates this process by controlling C3b deposition and activation.
Complement activation occurs in the substantia nigra of PD patients, with evidence of altered complement regulation[@bonotis2016]:
Complement activation contributes to motor neuron injury in ALS[@zhou2020]:
In multiple sclerosis, complement contributes to demyelination and oligodendrocyte loss[@zipp2010]:
Complement proteins including CFH participate in normal brain physiology:
Synaptic Pruning: During development, complement C1q and C3 tag synapses for elimination by microglia. CFH regulates this process to ensure appropriate pruning[@song2020].
Microglial Education: Complement components guide microglial synaptic surveillance and response to injury[@wood2022].
Multiple therapeutic strategies targeting complement in neurodegenerative diseases are under development[@jiang2022]:
| Drug | Target | Approval Status | Potential CNS Use |
|---|---|---|---|
| Eculizumab | C5 | PNH, aHUS | Investigational |
| Ravulizumab | C5 | PNH, aHUS | Investigational |
| Avacopan | C5aR1 | ANCA vasculitis | Investigational |